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Abstract
Introduction: Endosomal toll-like receptors (TLRs) have recently emerged as potential contributors to the
inflammation observed in human and rodent models of rheumatoid arthritis (RA). This study aims to evaluate the
role of endosomal TLRs and in particular TLR7 in the murine collagen induced arthritis (CIA) model.
Methods: CIA was induced by injection of collagen in complete Freund’s adjuvant. To investigate the effect of
endosomal TLRs in the CIA model, mianserin was administered daily from the day of disease onset. The specific
role of TLR7 was examined by inducing CIA in TLR7-deficient mice. Disease progression was assessed by measuring
clinical score, paw swelling, serum anti-collagen antibodies histological parameters, cytokine production and the
percentage of T regulatory (Treg) cells.
Results: Therapeutic administration of mianserin to arthritic animals demonstrated a highly protective effect on
paw swelling and joint destruction. TLR7-/- mice developed a mild arthritis, where the clinical score and paw
swelling were significantly compromised in comparison to the control group. The amelioration of arthritis by
mianserin and TLR7 deficiency both corresponded with a reduction in IL-17 responses, histological and clinical
scores, and paw swelling.
Conclusions: These data highlight the potential role for endosomal TLRs in the maintenance of inflammation in
RA and support the concept of a role for TLR7 in experimental arthritis models. This study also illustrates the
potential benefit that may be afforded by therapeutically inhibiting the endosomal TLRs in RA.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune
inflammatory disease that affects 1% of the population.
Disease progression is characterized by a destructive
inflammation of the joints, which can lead to progressive
disability and a reduced life expectancy. The synovial
membrane in RA is infiltrated by activated immune cells,
most abundantly macrophages and T cells, resulting in
the chronic production of pro-inflammatory cytokines
and matrix metalloproteinases, leading to inflammation
and cartilage and bone degradation [1]. The treatment of
RA has been revolutionized by the development of biolo-
gical therapies specifically targeting immune mediators.
These include tumor necrosis factor (TNF) [2], interleu-
kin-1 (IL-1), the IL-6 receptor, B cells, and activated
T cells (reviewed in [3]). However, these biologics are not
orally available and are expensive to manufacture; their
cost severely limits use. Side effects are also common; for
example, systemic inhibition of TNF confers an increased
risk of infection in patients [4]. Thus, there is a require-
ment for cheaper and more targeted therapies to treat
RA.
To improve the therapies available to patients, it is
essential to gain a better understanding of the mechan-
isms that sustain inflammation in RA. Despite the effec-
tiveness of biological therapies in many patients, disease
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activity usually resumes once treatment has stopped. This
indicates that the upstream mechanisms that generate
inflammation are still functional and most likely unaf-
fected by these treatments. Many studies from both mur-
ine and human models have suggested a role for a family
of innate immune receptors, the Toll-like receptors
(TLRs) in RA pathogenesis [5].
TLRs form part of a network of receptors that alert the
host to the presence of infection and tissue damage.
TLRs can be classified into two distinct groups on the
basis of cellular distribution and ligand repertoire. Cell
surface-expressed TLRs 1, 2, 4, 5, and 6 recognize ligands
of mainly bacterial and fungal origin, whereas TLRs 3, 7,
8, and 9 are expressed intracellularly in endosomes and
detect nucleic acids from bacteria and viruses [6]. TLR
activation induces a strong inflammatory response, which
is characterized by the increased expression of TNF
among many other mediators. In addition to pathogen-
associated ligands, TLRs can engage a number of endo-
genous molecules that can be produced during tissue
damage and are often found at the sites of chronic
inflammation [7].
The concept of endogenous ligand-driven activation of
TLRs makes these receptors potential candidates for the
induction or maintenance (or both) of chronic inflamma-
tory conditions [8]. A potential role has been emerging for
the endosomal TLRs in autoimmune diseases such as RA
and systemic lupus erythematosus (SLE), in which it has
become apparent that DNA- and RNA-associated autoan-
tigen immune complexes can activate B cells and dendritic
cells through activation of TLRs [9-11]. Clinical data sup-
porting this concept have come from the study of patients
deficient in Unc93B1 [12], a protein required for TLR3, 7,
8, and 9 signaling [13]. Unc93b1-deficient patients show
increased numbers of naïve autoreactive B cells in the per-
iphery, similar to patients with RA [12], but do not
develop autoreactive antibodies or autoimmunity [12].
In a previous study, we identified an off-target effect of
the antidepressant mianserin and showed that it inhibited
the activation of the endosomal TLRs 3, 7, 8, and 9 and
significantly decreased TNF and IL-6 production from
human RA synovial membrane cultures [14]. In the pre-
sent study, we set out to investigate the role of the endo-
somal TLRs in vivo in an experimental arthritis model
using mianserin. Previous work had suggested that TLR8
may be of importance in a human model of RA [14].
However, with no defined ligand, the role of murine
TLR8 remains unclear. One study suggests that murine
TLR8 may not be functional [15] -leaving murine TLR7
more closely mirroring the behavior of human TLR8.
Murine TLR7 and human TLR8 are activated by the
same ligands [15-17] and induce TNF production from
macrophages, a key mediator of the disease process in
RA [18]. Thus, in this study, we chose to focus on the
role of TLR7 in the murine CIA model using TLR7-/-
mice.
Materials and methods
Reagents
Cell culture reagents used were penicillin/streptomycin,
Roswell Park Memorial Institute (RPMI) 1640, and Dul-
becco’s modified Eagle’s medium (DMEM) obtained from
Cambrex (Verviers, Belgium); fetal bovine serum (FBS)
from PAA (Pasching, Austria); and tissue culture-grade
beta mercaptoethanol (2-ME) from Gibco-Invitrogen
(Paisley, UK). The TLR ligands used were chloroform-
extracted, Escherichia coli lipopolysaccharide (LPS), resi-
quimod (R-848), and CpG (ODN M326) from InvivoGen
(San Diego, CA, USA). Mianserin hydrochloride was pur-
chased from Sequoia Research Products (Pangbourne,
UK). All reagents were tested for LPS contamination by
using the limulus amebocyte lysate (LAL) assay from
Cambrex (Charles City, IA, USA) [19] and were found to
be below 10 pg/mL. Macrophage colony-stimulating factor
(M-CSF) was purchased from PeproTech (London, UK).
Cell culture
Murine bone marrow-derived macrophages (BMMs)
were obtained from femurs of male C57BL/6 mice and
were cultured for 6 days with DMEM containing FBS
(20% vol/vol), 100 U/mL penicillin/streptomycin, 2-ME
(50 μM), and 10 ng/mL M-CSF. Draining lymph node
cells (DLNCs) were isolated from the inguinal lymph
nodes. Cells were cultured in 96-well plates at a density
of 2 × 105 per well in RPMI 1640 containing 10% heat-
inactivated fetal calf serum (vol/vol), 100 U/mL penicil-
lin/streptomycin, 2-ME (50 μM), and 1% L-glutamine.
Cells were cultured alone or in the presence of 50 μg/mL
type II collagen or 100 ng/mL anti-CD3 monoclonal anti-
body. Supernatants were collected after 48 hours for the
determination of IL-17 and interferon-gamma (IFNg).
Cell viability was not significantly affected over this time
period when examined by the 3-[4,5 dimethylthiazol-2-
yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay
(Sigma-Aldrich, St. Louis, MO, USA) [20].
Cytokine enzyme-linked immunosorbent assay
Sandwich enzyme-linked immunosorbent assays (ELI-
SAs) were employed to measure RANTES (Regulated
upon Activation, Normal T-cell Expressed, and
Secreted) (R&D Systems, Abingdon, UK) and TNF,
IFNg, and IL-17 (Becton Dickinson, Oxford, UK) in
accordance with the instructions of the manufacturer.
Absorbance was read on a spectrophotometric ELISA
plate reader (Multiscan Biochromic; Thermo Labsys-
tems, Cambridge, UK) and analyzed by using Ascent
software version 2.6 (Thermo Labsystems, Cambridge,
UK).
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Collagen-induced arthritis
CIA was induced and the clinical score was assessed daily
as previously described [21,22] in three independent
experiments for both the mianserin and the TLR7-/-
experiments. DBA/1 and C57BL/6 mice were purchased
and housed in the same unit under conditions identical to
those of the TLR7-/- animals. Briefly, 8- to 12-week-old
male DBA/1 or C57BL/6 wild-type (WT) or TLR7-/- mice
were immunized subcutaneously at the base of the tail
with 200 μg of bovine or chicken type II collagen, respec-
tively, emulsified in complete Freund’s adjuvant (CFA)
(Difco Laboratories, West Molesey, UK). Mianserin treat-
ment was administered therapeutically, starting on the day
of onset of arthritis symptoms by interperitoneal injection
daily for 7 days in DBA/1 mice. Paw swelling was assessed
daily by measuring hind paw thickness by means of cali-
pers. The onset of arthritis was considered to be the day
that erythema or swelling (or both) were first observed,
and arthritic mice were given a clinical score per limb
from 0 to 3, with 0 = normal, 1 = slight erythema or swel-
ling (or both), 2 = pronounced edematous swelling, and
3 = joint deformity with ankylosis, resulting in a maximum
score of 12 per animal. This research was approved by the
Ethical Review Process Committee of the Kennedy Insti-
tute of Rheumatology and the UK Home Office (PPL 70/
6533).
Measurement of IgG1 and IgG2a/c antibodies
Anti-CII IgG levels were measured in mouse sera as pre-
viously described [23] with modifications. Briefly, micro-
titer plates were coated with 2 μg/mL of CII dissolved in
0.05 M Tris-HCl and 0.2 M NaCl (pH 7.4) overnight at
4°C. After blocking for 1 hour with 2% bovine serum
albumin, sera were titrated in parallel to a standard sam-
ple. A standard consisting of pooled sera was used for the
TLR7-/- experiments. For isotype quantitation, sheep
anti-mouse IgG1 and IgG2a/c (BD Pharmingen, San
Diego, CA, USA) linked to horseradish peroxidase were
used at a dilution of 1:1,000. The plates were developed
by using tetramethyl benzidine as the substrate, and opti-
cal density was measured at 450 nm. Data were presented
as arbitrary units.
Histological assessment of arthritis
On completion of the experiment, the first limb to show
evidence of arthritis was processed for histology. The
limb was fixed, decalcified, and embedded before section-
ing and staining with hemotoxylin and eosin. Histopatho-
logical severity was scored in the tarsometatarsal,
metatarsophalangeal, and interphalangeal joints by
microscopy in a blinded fashion. The histological severity
of arthritis was graded as follows: 0 = normal; 1 = mini-
mal synovitis, cartilage loss, and bone erosions limited to
discrete foci; 2 = synovitis and erosions present but
normal joint architecture intact; and 3 = synovitis and
extensive erosions present and joint architecture dis-
rupted. The data are shown as the average score from the
three joints for each mouse.
Flow cytometry
DLNCs were incubated with CD4-conjugated antibody
(BD Pharmingen) for 30 minutes at 4°C. Unstimulated
cells were stained with FoxP3 antibody (eBioscience,
Hatfield, UK) in accordance with the instructions of the
manufacturer. Cells were acquired and analyzed on
FACS Canto II by using FACSDIVA software (BD
Pharmingen).
Real-time polymerase chain reaction
Comparative mRNA levels of cytokines were assessed in
the joints of mice. RNA was extracted by using the
RNAeasy mini kit (Qiagen, Crawley, UK) in accordance
with the instructions of the manufacturer. Generation of
cDNA was carried by using the ABI High-capacity reverse
transcription system with random hexamer primers in
accordance with the protocol of the manufacturer
(Applied Biosystems Inc., Warrington, UK). Amplification
of cDNA was performed on an ABI AB7900HT real-time
polymerase chain reaction machine in a 384-well plate by
using TaqMan Gene Expression Assays sets from the ABI
inventoried library for all genes and mouse hypoxanthine
phosphoribosyl-transferase (HPRT) control. The relative
concentration of each gene of interest was calculated by
using the (ΔΔCt) method [24] and expressed as relative
units by using a WT arthritic mouse as a calibrator after
normalizing against HPRT.
Statistical methods
Mean, standard deviation (SD), standard error of the mean
(SEM), and statistical significance were calculated by using
GraphPad version 3 (GraphPad Software Inc., La Jolla,
CA, USA). For statistical analysis, a one-tailed t test of
paired data was used with a 95% confidence interval. SEM
was used for pooled experimental data, whereas SD was
used in graphs showing representative experiments. A
one-tailed Mann-Whitney test was used with a 95% confi-
dence interval for the CIA data (***P < 0.001, **P < 0.01,
and *P < 0.05).
Results
Mianserin inhibits cytokine production induced by TLR3,
7, and 9 from murine bone marrow-derived macrophages
In a previous study, we demonstrated that mianserin
could inhibit the activation of TLRs 3, 7, 8, and 9 but not
the cell-surface TLRs 1/2, 4, and 5 in primary human
cells [14]. Before testing the effects of mianserin in CIA,
it was essential to confirm that mianserin was able to
inhibit endosomal TLR activation in murine primary
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macrophages (BMMs). Mianserin inhibited the produc-
tion of TNF upon activation of TLR7 and 9, but not
TLR4, in BMMs (Figure 1a). RANTES was used as a
readout for TLR3 activation because polyinosinic:polycy-
tidylic acid (poly I:C) is a weak inducer of TNF in BMMs.
Upon TLR3 stimulation, mianserin also dose-depen-
dently inhibited the production of RANTES (Figure 2b).
TLR8 activation was not measured, as the mechanism of
activation of this receptor remains unclear at present.
Human TLR7 and 8 can be activated by singled-stranded
RNA (ssRNA) or resiquimod, but in murine cells only
TLR7 (not TLR8) responds to these ligands [15,17]. Cell
viability was not affected by mianserin as assessed by the
MTT assay (Sigma-Aldrich) [20] (data not shown).
Mianserin suppresses disease progression in CIA
At the same concentration as was previously shown for
inhibition of human TLR signaling, mianserin inhibited
the spontaneous production of TNF and IL-6 from
human synovial membrane cultures [14]. To investigate
whether the beneficial effects of mianserin would also be
observed in vivo, the murine CIA model was chosen, as it
shows many similarities to human RA, such as a compar-
able synovitis, bone erosion, and pannus formation [25].
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Figure 1 Mianserin inhibits Toll-like receptor (TLR) 3, 7, and 9 signaling in murine macrophages. Murine bone marrow-derived
macrophages were pre-incubated for 30 minutes with mianserin and then stimulated with (a) 100 ng/mL lipopolysaccharide (LPS), 1 μg/mL
resiquimod (R-848), and 500 μM ODN M326 for 6 hours before measuring tumor necrosis factor (TNF) in the supernantants or (b) 20 μg/mL
polyinosinic:polycytidylic acid (poly I:C) for 24 hours before measuring RANTES production in the supernantants. Data are shown as a percentage
of the TLR ligand-only response at 30 μg/mL mianserin and as a representative graph showing the effect of a range of concentrations of
mianserin. (c) Cell viability was measured by 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay. **P < 0.01, ***P < 0.001.
RANTES, Regulated upon Activation, Normal T-cell Expressed, and Secreted; unstim, unstimulated.
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Figure 2 Mianserin inhibits disease progression, paw swelling, and interleukin-17 (IL-17) production in the collagen-induced arthritis
(CIA) model of arthritis. DBA/1 CIA mice were therapeutically given an intraperitoneal injection of vehicle (phosphate-buffered saline,) or 10
mg/kg mianserin once a day for 7 days, starting on the day of disease onset. Mice were assessed for (a) clinical score (n = 20 mice per group)
and (b) paw swelling on a daily basis (n = 15 to 17 mice per group). (c, d) Arthritis was scored histologically as described in Materials and
methods for the vehicle control group (n = 18) and the mianserin-treated group (n = 17). (e) Mice were bled on day 7, and serum levels of IgG1
and IgG2a anti-collagen antibodies were measured (n = 20). Frames (a-e) show data pooled from three separate experiments. (f) On day 10 after
disease onset, cells from draining inguinal lymph nodes were cultured and stimulated with bovine type II collagen (BCII) (50 mg/mL) or anti-CD3
monoclonal antibody (100 ng/mL) for 48 hours. Supernatants were analyzed for the production of interferon-gamma (IFNg) and IL-17 by
enzyme-linked immunosorbent assay. Each point represents an individual animal (n = 8). *P < 0.05, **P < 0.01, ***P < 0.001. unstim,
unstimulated.
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Mice were treated with mianserin by using a therapeutic
rather than a prophylactic protocol. Mianserin was able
to dramatically reduce the clinical score (Figure 2a) and
gave a significant reduction in paw swelling (Figure 2b).
Increasing the dose to 25 mg/kg gave no added benefit
(data not shown). Histological analysis of hind paws in
mice treated for 7 days after onset showed that mianserin
had a beneficial effect on preserving joint architecture
and decreasing both bone destruction and cell infiltration
into the joint (Figure 2c). Pooled data from all mice
clearly showed the significant effect of mianserin on the
histological score (Figure 2d). As would be expected of
an intervention given therapeutically, mianserin had no
effect on serum levels of anti-collagen IgG1 or IgG2a
(Figure 2e).
IL-17-producing CD4+ T cells have been shown to be
important contributors to pathogenesis in the CIA model
[26]. Thus, the decreased disease progression observed in
the mianserin-treated group might be due to reduced
numbers of pathogenic T cells. To test this hypothesis,
DLNCs from the mice treated with mianserin showed a
significant decrease in anti-CD3-induced IL-17 produc-
tion; a strong trend toward lower production of antigen-
specific IFNg and IL-17 was observed, although this did
not reach statistical significance (Figure 2f). In contrast,
the total numbers of CD4+ cells and the percentage of
CD4+foxp3+ cells were unchanged in the DLNs of mian-
serin-treated mice (data not shown).
TLR7 is required for the maintenance of disease in CIA
The ability of mianserin to inhibit endosomal TLR activ-
ity in BMM and effectively suppress disease progression
in CIA raises the possibility that the anti-inflammatory
activity of mianserin is due to its ability to dampen one
or more of the endosomal TLR responses. Data from the
human RA model previously suggested that TLR8 was a
key contributor to cytokine production from human
synovial membrane tissue [14]. However, since the func-
tion of murine TLR8 is unclear at present [17,27], its
paralogue murine TLR7 (which more closely reflects the
function of human TLR8) was investigated by using
TLR7-/- mice.
CIA was induced in TLR7-/- and control C57BL/6 mice
and disease was assessed as described above. Clinical fea-
tures were measured only in mice exhibiting clinical signs
of arthritis. TLR7 deficiency significantly compromised the
clinical score, progression in paw swelling, and number of
paws affected (Figure 3a-c, respectively). The percentage
incidence was also decreased but this decrease did not
reach statistical significance (Figure 3c). Histological analy-
sis of the affected joints from arthritic TLR7-/- mice at day
10 after onset clearly showed a reduction in disease para-
meters with minimal inflammation and synovitis and a
clear preservation of the joint architecture (Figure 3d, e).
Protection from CIA progression in TLR7-deficient mice is
associated with decreased antigen-specific IL-17
production and increased Treg cells
We questioned whether the reduced arthritis observed in
TLR7-/- animals was due to a failure to elicit a robust
immune response to Mycobacterium tuberculosis (MTB),
the active ingredient in the adjuvant used in the CIA
model. TLR7 deficiency did not affect the innate immune
response of BMMs to MTB (data not shown), suggesting
an adjuvant-independent regulatory mechanism. Further-
more, TLR7-/- mice actually mounted a stronger B-cell
response to type II collagen (which is essential for disease
induction in CIA) compared with their WT counterparts,
indicating that the humoral arm of the immune response
in TLR7-/- mice was not deficient (Figure 4a).
Supporting the reduction in disease parameters,
DLNCs from TLR7-/- mice produced significantly less
antigen-specific IL-17 in response to collagen stimulation
ex vivo (Figure 4b), indicating that TLR7 may be involved
in regulating T helper 17 (TH17) responses. Interestingly,
a trend toward increased IFNg production was observed
but was not significant (Figure 4c). Subsequently, the
involvement of TLR7-/- T cells was investigated. The
overall percentage of CD4+ T cells was markedly reduced
in the joints but not the DLNs of TLR7-/- mice compared
with WT mice (Figure 4d, e), reflecting a reduced level of
inflammatory cell infiltration in the absence of signaling
via TLR7. This was supported by a reduction in the
mRNA levels of TNFa, IL-1, IL-6, IL-17, and IFNg
(Figure 5) and a decrease in TH17 cells in the joints of
TLR7-/- when compared with controls (data not shown).
In contrast, the percentage of CD4+foxp3+ cells was sig-
nificantly higher in the joints of TLR7-/- mice compared
with WT controls, despite the fact thatthe total percen-
tage of CD4+ cells was significantly lower in TLR7-/- ani-
mals (Figure 4e). A trend toward increased regulatory T
(Treg) cells in the DLNs of TLR7
-/- animals was also
observed but did not reach significance (Figure 4d).
Discussion
In this study, we set out to investigate the role of endoso-
mal TLRs in a murine model of RA by using mianserin, an
antidepressant that can inhibit endosomal TLR signaling
[14]. Therapeutic administration of mianserin decreased
disease progression and appreciably preserved the joint
architecture in the CIA model, suggesting a possible role
for one or more of these TLRs in the maintenance of dis-
ease. This result was consistent with previous data, in
which we showed that mianserin could inhibit sponta-
neous production of TNF and IL-6 from human RA syno-
vial membrane cultures [14]. Conversely, some reports
have suggested that 5HT-2A receptor antagonists, includ-
ing mianserin, can cause adverse drug reactions, including
joint problems [28,29]. However, the discrepancy between
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Figure 3 Suppression of arthritis in TLR7-deficient mice. TLR7-/- (n = 12) and control C57Bl/6 (n = 14) mice were immunized with chicken
collagen in complete Freund’s adjuvant. Arthritis was assessed by (a) clinical score and (b) paw swelling on a daily basis from the first day of
disease onset. Data are pooled from three independent experiments. (c) The number of paws affected and the disease incidence were recorded
for each group from three separate experiments. (d) The first affected joint was collected after 10 days of disease onset and was fixed and
stained with hematoxylin and eosin. (e) Arthritis was scored histologically for TLR7-/- (n = 9) and control C57Bl/6 (n = 10) mice as described in
Materials and methods and pooled from two independent experiments. *P < 0.05, **P < 0.01. TLR, Toll-like receptor; WT, wild-type.
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Figure 4 Arthritis in TLR7-/- mice is associated with decreased IL-17 levels and increased Treg cells. (a) Mice from Figure 3 were bled on
day 10, and serum levels of IgG1 and IgG2a/c anti-collagen antibodies were measured by enzyme-linked immunosorbent assay as described in
Materials and methods. (b, c) Draining lymph node cells (DLNCs) were isolated 10 days after disease onset and stimulated with 100 ng/mL anti-
CD3 monoclonal antibody or 50 μg/mL chicken collagen, and supernatants were collected for the measurement of IL-17 (b) and interferon-
gamma (IFNg) (c). (d) DLNCs or cells liberated from the affected joints (e) were stained with conjugated antibodies to CD4 and foxp3 to
determine the percentage of Treg cells. *P < 0.05, **P < 0.01. IL-17, interleukin-17; LN, lymph node; No stim, no stimulation; N.S., not significant;
TLR, Toll-like receptor; Treg, T regulatory; WT, wild-type.
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these reports and our studies may be explained by the fact
that the inhibition of TLRs by mianserin is an off-target
effect observed only at doses that are higher than would
be safe to administer clinically [30]. Thus, mianserin may
produce differing effects via distinct mechanisms when
used at low or high concentrations. Accordingly, mian-
serin does not represent a useful anti-arthritic drug for the
clinic. However, these data highlight the potential benefit
that might be provided by the development of a more spe-
cific set of inhibitors of the endosomal TLRs.
Previous data from a human model of RA had sug-
gested a role for TLR8 in the production of TNF [14];
however, extrapolating this finding across species
becomes difficult when considering the role of TLR8.
Whereas human TLR7 and 8 can be activated by ssRNA
or resiquimod, only TLR7 (and not TLR8) responds to
these ligands in rodents [15,17]. This distinction was
recently suggested to be due to a variation between spe-
cies in leucine-rich repeats 14-15 of TLR8 [31]. The
mechanism of murine TLR8 activation and the function
of this receptor remain unclear at present. Nonetheless,
its functional paralogue murine TLR7 behaves in a man-
ner similar to human TLR8; both receptors are known to
be activated by the same natural ligand, ssRNA, and can
induce TNF production from macrophages [17]. Thus,
this study focused on the role of TLR7, rather than
TLR8, in the CIA model.
Here, we show that TLR7 deficiency resulted in a
decrease in clinical and histological scores, paw swelling,
and disease incidence. Compared with control WT mice
in which the clinical score progresses steadily after dis-
ease onset, the clinical score in the majority of TLR7-/-
mice failed to increase. Interestingly, disease resolved in
about 20% of arthritic mice within 5 days of onset. Initia-
tion of CIA requires CFA, which is a mixture of mineral
oil and heat-inactivated MTB; thus, it was possible that
TLR7 deficiency may haveprevented the induction of
arthritis. Encouragingly, both BMMs and dendritic cells
from TLR7-deficient mice responded to heat-inactivated
MTB, producing TNF levels comparable to those of cells
from WT mice (data not shown). This suggested that the
innate immune response to MTB remained intact in
TLR7-deficient mice.
Another important mechanism in the initiation of CIA
is the generation of anti-collagen antibodies; these antibo-
dies have also been shown to be capable of transferring
disease to immunocompromised animals [32,33]. In a
murine model of spontaneous lupus, it was shown that
TLR7 deficiency results in decreased serum levels of IgG2a
and IgG3 isotypes [34], which are among the pathogenic
isotypes in autoimmune diseases such as SLE [35]. How-
ever, it was of interest that we observed that the lack of
TLR7 resulted in higher levels of anti-collagen IgG1 as
well as IgG2a/c in the serum of arthritic mice when com-
pared with WT controls, suggesting that TLR7 signaling
has a negative impact on TH1 responses in the CIA model.
Why TLR7 deficiency resulted in opposing effects in two
animal models is not understood but may be due to the
direct injection of antigen or the presence of adjuvant in
the CIA model, perhaps implicating antigen presentation
in this discrepancy. Indeed, the increased level of the TH1-
associated IgG2a/c isotype may have supported the increase
in IFNg production from stimulated DLNCs. Of the TH1
responses, IFNg in particular has been associated with pro-
tection from disease in experimental models of arthritis
(reviewed in [36]). One way in which IFNg suppresses dis-
ease is by inhibiting IL-17 production [37]. Likewise,
arthritic TLR7-/- animals showed a significant decrease in
IL-17/TH17 and an increase in Treg cells, pointing to a
potential role for TLR7 in regulating T-cell plasticity or
the balance between TH17 cell/Treg cell responses or both.
However, on the basis of our findings, it was not possible
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Figure 5 TLR7-/- mice have decreased cytokine expression in the paw tissue. RNA was isolated from whole affected paws of control C57Bl/
6 wild-type (WT) (n = 4 or 5) or TLR7-/- (n = 3 or 4) mice. Real-time polymerase chain reaction was performed to measure levels of tumor
necrosis factor-alpha (TNFa), interleukin-1-beta (IL-1b), IL-6, IL-17, and interferon-gamma (IFNg) using ABI primers. *P < 0.05. TLR, Toll-like receptor.
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to establish whether TLR7 deficiency has a direct effect on
T cells or acts indirectly via the antigen-presenting cells.
Treg cells have also been implicated in the control of
inflammatory arthritis in animal models (reviewed in [36]).
TLR7 ligation is reported to suppress foxp3 expression
[38] and thus may explain the increase in Treg cells in
TLR7-deficient arthritic mice. However, no change in the
level of Treg cells was observed in DLNs of mianserin-trea-
ted mice and this may reflect the difference of specific
TLR7 deficiency as opposed to pan-endosomal TLR
inhibition.
However, our data do not exclude a role for other TLRs.
In the rat pristane model of arthritis, recent studies have
shown upregulation of TLR3 in the rat synovium, aggrava-
tion of arthritis by the TLR3 ligand poly I:C, and ameliora-
tion of disease by TLR3 RNA interference in vivo [39,40].
TLR9 inhibitors have also been reported to delay disease
onset and severity in the rat pristane model [41].
Most studies of murine experimental arthritis have
suggested a contribution from TLR4 to the maintenance
of inflammation [42-44]. A role for TLR7 may, in fact,
be complementary to these studies, as TLR7-induced
type I IFN has been shown to enhance TLR4 activation,
most notably in cells taken from patients with RA [45].
Involvement of TLR7 in the maintenance of inflamma-
tion in CIA is also in keeping with other studies of
inflammatory arthritis models. Low-dose activation of
TLR7 with a small synthetic ligand has been shown to
induce tolerance of TLR2, 7, and 9 signaling and to sup-
press disease in a serum transfer model of arthritis [46].
In addition, a recent study of pristane-induced arthritis
has shown that splenocytes from an arthritic animal can
transfer disease after re-stimulation with heterogeneous
nuclear ribonucleoprotein (hnRNP) antigens that acti-
vate TLR7 and 9 [47]. Intra-articular lentiviral delivery
of TLR7 short-hairpin RNA was recently shown to
decrease IL-1 and IL-6 expression in synovial tissue of
CIA rats [48]. This is in agreement with our data show-
ing a decrease in IL-1, IL-6, and other cytokines in the
paw tissue from the TLR7-/- CIA mice.
Conclusions
In summary, this study has uncovered an important role
for TLR7 in CIA which complements other animal
model studies [46,47] and shows a role comparable to
that of its human homologue, TLR8, in RA [14]. Given
that the activity of TLR7 and 8 can be modulated by
small synthetic agents such as mianserin, these receptors
may provide amenable targets for the development of
new therapeutics for RA.
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